The original success of Sildenafil undeniably reshaped the drug landscape, but placing funds in companies primarily reliant on generic versions presents a uncertain picture. Although early returns were significant, the expiration of patents and the rise Pharma of discounted alternatives have weakened sales. Consequently, a thorough assessment of on